Urinary Tumor Markers for Bladder Cancer
Customize your policy alerts
Sign up for Blue Cross Blue Shield - Oklahoma Policy CPCPLABO38 alerts
Get alerted when Policy CPCPLABO38 changes without checking for updates manually.
Monitor payer policy activity
Defines BCBS Oklahoma reimbursement and clinical-use criteria for urinary tumor marker tests for bladder cancer (e.g., BTA, NMP22, UroVysion FISH, ImmunoCyt) and which indications are reimbursable for plan members and providers.
Added code 0452U to the document.
Previously added code 0549U is recorded in update history.
Document updated with literature review; reimbursement information unchanged.
Coverage Criteria for Urinary Tumor Marker Testing
inv-01: Reimbursable adjunct indications
Reimbursable uses (may be reimbursable when the test is used as an adjunct in the following situations):
These are stated as reimbursable adjunct uses in the policy.
inv-02: Not reimbursable indications
Tests are not reimbursable for the following indications:
Policy explicitly lists these as not reimbursable for the named tests.
inv-03: Tests not reimbursable for excluded uses
Specific tests not reimbursable for the non-reimbursable indications include:
Policy enumerates these tests in the not reimbursable section.
This policy takes a selective coverage stance for urinary tumor marker testing: certain urinary biomarkers may be reimbursable only when used as an adjunct in specific clinical situations. Specifically, tests such as bladder tumor antigen (BTA), nuclear matrix protein (NMP22), and UroVysion FISH may be reimbursable when used as an adjunct to resolve atypical or equivocal cytology or to monitor high-risk, non-muscle invasive bladder cancer, and fluorescence immunocytology (ImmunoCyt) may be reimbursable as an adjunct to cystoscopy or cytology in monitoring individuals with bladder cancer. Conversely, the policy does not reimburse these urinary tumor marker tests for evaluation of hematuria, screening of asymptomatic individuals, diagnosing symptomatic individuals, or for any other indications not specifically listed above.
Tests listed in this policy are considered not medically necessary (not reimbursable) when used outside the enumerated adjunct uses. Examples of non‑reimbursable uses include testing for the evaluation of hematuria, screening for bladder cancer in asymptomatic individuals, diagnosing bladder cancer in symptomatic individuals, or any other indications not explicitly identified as reimbursable adjunct uses. The policy specifically names urinary biomarkers (BTA, NMP22, UroVysion FISH) and fluorescence immunocytology (ImmunoCyt) as not reimbursable for these excluded indications.
Coding and Billing
Provider Actions and Billing Guidance
Verify coding and prior authorization
Verify coding and prior authorization rules before submitting claims. Confirm plan-specific coverage and any prior authorization requirements for the listed or related laboratory procedure codes; failure to obtain required authorization may result in claim denial.
- Confirm whether prior authorization is required by the member's plan before performing testing.
- Verify that the submitted CPT/HCPCS code matches the actual test performed and latest coding updates.
Submit accurate documentation and coding
Providers must ensure claims are accurately coded and that complete supporting documentation is available upon request. Submit clinical documentation supporting medical necessity when requested.
- Use current, valid codes from HIPAA-approved code sets.
- Retain and provide medical records, test reports, and clinical notes if requested for claim review.
Non-reimbursable indications trigger denial
Submit claims using industry-standard code combinations and expect claim review. Claims lacking appropriate documentation, incorrect codes, or billed for non-reimbursable indications (see policy Reimbursement Information) may be denied.
- Claims are subject to code edit protocols and coding software logic.
- If requested, provide additional documentation to support the service.
- Services billed for non-reimbursable indications (e.g., screening asymptomatic individuals for bladder cancer with urinary biomarkers) will be denied.
Providers are responsible for following plan documents and reimbursement criteria; review plan-specific benefit documents for product-specific rules. Blue Cross and Blue Shield of Oklahoma may interpret and apply this policy with discretion.
- Review member's Certificate of Health Care Benefits, benefit booklet, or Summary Plan Description for coverage details.
- BCBSOK retains discretionary authority in applying this policy.
Background
Urinary tumor markers are laboratory assays performed on urine (for example, protein, nuclear matrix proteins, or cytogenetic tests) that serve as adjunctive tools in the diagnosis and surveillance of bladder cancer rather than as stand‑alone diagnostic tests. In clinical practice these markers — including BTA, NMP22, UroVysion FISH, and ImmunoCyt — can provide additional information when cytology is atypical or equivocal or when monitoring patients with high‑risk, non‑muscle invasive bladder cancer. Their performance and role vary by test and indication, and this policy limits reimbursement to those adjunctive scenarios rather than routine screening, hematuria evaluation, or primary diagnosis.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.